Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
A number of other equities research analysts also recently issued reports on the stock. Maxim Group downgraded shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold”.
Read Our Latest Stock Analysis on SLXN
Silexion Therapeutics Stock Performance
NASDAQ SLXN opened at $1.98 on Friday. The business’s 50-day moving average price is $5.70 and its 200 day moving average price is $140.28. Silexion Therapeutics has a twelve month low of $1.82 and a twelve month high of $777.12. The company has a market capitalization of $455,400.00, a PE ratio of -0.05 and a beta of -0.30.
Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($13.70) EPS for the quarter, beating the consensus estimate of ($218.40) by $204.70. Equities analysts predict that Silexion Therapeutics will post -112.71 EPS for the current year.
Silexion Therapeutics Company Profile
Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.
Recommended Stories
- Five stocks we like better than Silexion Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
